In this study, the Cancer Research UK-funded scientists will establish the targets for the vaccine. They will find out which proteins on the surface of early-stage ovarian cancer cells are most strongly recognized by the immune system and how effectively the vaccine kills mini-models of ovarian cancer called organoids.